Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +16

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine · 2018 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +16

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

David P. Steensma, Rafael Bejar, Siddhartha Jaiswal et al. · Blood · 2015 · 1.9K citations · Full text

Medicine, Hematology, Pathology +16

Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics

Sarah S. Kalia, Kathy Adelman, Sherri J. Bale et al. · Genetics in Medicine · 2016 · 1.7K citations · Full text

Life Sciences, Genetics, Molecular Genetics +16